<DOC>
	<DOCNO>NCT01530555</DOCNO>
	<brief_summary>To assess tolerability efficacy rabbit antithymocyte globulin ( ATG , Thymoglobuline® ) ciclosporin ( CSA ) first line treatment patient acquire severe aplastic anaemia ( SAA ) , patient non-severe aplastic anaemia ( NSAA ) transfusion dependent . To compare response rate combination rabbit ATG ( Thymoglobuline® CSA pilot study response rate observe series match AA patient ; treat 1994 combination horse ATG ( Lymphoglobuline® ) CSA ; obtain EBMT database ( comparative study ) .</brief_summary>
	<brief_title>Prospective Phase II Study Rabbit Antithymocyte Globulin ( ATG , Thymoglobuline® , Genzyme ) With Ciclosporin Patients With Acquired Aplastic Anaemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1 . To define aplastic anaemia must least two follow : ( 1 ) haemoglobin &lt; 10g/dl ; ( 2 ) platelet count &lt; 50 x 109/l ; ( 3 ) neutrophil count &lt; 1.5 x 109/l , hypocellular bone marrow bone marrow biopsy 2 . Time diagnosis study registration ≤ 6mths 3 . No prior treatment except haemopoietic growth factor give 4 week , androgen . 4 . Age ≥ 16yrs ( ≥ 18yrs Germany accordance German law ) , upper age limit . Exclusion criterion : 1 . Eligibility HLAmatched sibling donor transplant SAA patient 2 . Prior therapy ATG CSA 3 . Haematopoeitic growth factor 4 week study enrollment 4 . Diagnosis Fanconi anaemia , dyskeratosis congenita congenital bone marrow failure syndrome 5 . Evidence myelodysplastic disease 6 . Paroxysmal nocturnal haemoglobinuria evidence significant haemolysis , history PNH associate thrombosis PNH clone &gt; 50 % flow cytometry 7 . Diagnosis previous history carcinoma ( except local cervical , basal cell , squamous cell , melanoma ) 8 . Subject pregnant ( e.g . positive HCG test ) breast feed 9 . Severe uncontrolled infection unexplained fever &gt; 38oC 10 . Subjects hepatic , renal cardiac , metabolic concurrent disease severity life expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>